Article Figures & Data
Figures
- FIG 1
Flow diagram showing the number of women eligible for inclusion during the study period and the number of women excluded from the analysis, with reasons.
Tables
- TABLE 1
Baseline characteristics of women included in the test accuracy analysis, with valid urine samples, self-collected cervicovaginal samples, and provider-collected cervical samples
↵a Other races included American Indian/Alaskan Native (n = 4), Asian (n = 9), black-Indian (n = 1), white-black (n = 1), white-Asian (n = 2), Indian (n = 1), Mediterranean (n = 1), and Native Hawaiian/other Pacific Islander (n = 1).
- TABLE 2
Diagnostic test accuracy of the Onclarity hrHPV assay for detection of CIN2+ with different sample types, using the Onclarity CT cutoff value established for provider-collected samples for all sample types
↵a A CT cutoff value of ≤34.2 was used for all hrHPV subtypes except for HPV-16, for which the CT cutoff value was set at ≤38.3, according to FDA-approved thresholds for provider-collected specimens.
- TABLE 3
Test accuracy of the urine-based Onclarity hrHPV assay for detection of CIN2+ using different assay cutoff values
↵a The same CT cutoff value was used for all hrHPV subtypes detected by the Onclarity assay.
- TABLE 4
Agreement between Onclarity hrHPV test results for urine samples and those for self-collected cervicovaginal samples or provider-collected cervical samples
Supplemental material
- Supplemental file 1 -
Tables S1 to S6
PDF, 170K
- Supplemental file 1 -
